Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR09

Pharmacist-Led Oral Chemotherapy Monitoring Pilot Study and Assessment of Patient-Reported Outcomes and Adherence

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts, Chemotherapy

Presenter: Jessie Signorelli, PharmD, BCOP, Clinical Pharmacist–Hematology/Oncology, Massachusetts General Hospital, Boston

Co-Authors: Christopher Bell, PharmD, BCOP, Clinical Pharmacist–Hematology/Oncology, Pharmacy, Massachusetts General Hospital; Stephanie Monaco, PharmD, BCOP, Clinical Pharmacist–Hematology/Oncology, Pharmacy, Memorial Sloan Kettering Cancer Center

BACKGROUND: With the shift from intravenous to oral chemotherapy, patients are more responsible for self-monitoring medication adherence and adverse events (AEs).1-6 Specialty pharmacies may assess for adherence or AEs; however, no standard model is currently available for patient assessment.6-12 Oncology pharmacists are in a unique position to focus on the quality and safety of care for patients with cancer using oral chemotherapy, while providing communication between the patient, the physician, and specialty pharmacies. This pilot study aimed to monitor patients with leukemia who started treatment with oral chemotherapy.

OBJECTIVES: To characterize an oral chemotherapy monitoring program for patients with leukemia, and to quantify and describe the types of patient-centered activities performed.

METHOD: Patients with leukemia who started oral chemotherapy between July 2020 and February 2021 were included in this pilot study. Pharmacists performed education, medication reconciliation, and drug interaction screening at the initiation of oral chemotherapy. Pharmacists followed up with patients every 2 weeks, up to 2 months, and monthly thereafter. Follow-up included telephone calls and in-person visits. Adherence was assessed using the Morisky Medication Adherence Scale-8, and patient-reported outcomes were assessed using the revised Edmonton Symptom Assessment Scale (ESAS).7,8,11,12 AEs specific to each oral chemotherapy were also assessed. After each follow-up, providers were contacted, which was documented with assessment scores and recommendations.

RESULTS: Of the 32 patients who were screened, 19 patients were included in this pilot study. The oral chemotherapy used by patients included imatinib (N = 4), dasatinib (N = 5), ponatinib (N = 1), gilteritinib (N = 2), enasidenib (N = 1), and venetoclax (N = 6). All 19 patients received oral chemotherapy education, with 79% of the education sessions performed inpatient. In addition, 14 medication reconciliations were performed at oral chemotherapy initiation, and 53 reconciliations were performed at follow-up. We identified 14 drug interactions, 11 medications were discontinued, 9 medications were added, and 2 doses were changed. Pharmacists performed 62 follow-up encounters. A total of 26 adherence assessments demonstrated adherence (N = 21), medium adherence (N = 4), and low adherence (N = 1). Furthermore, 62 revised ESAS assessments were performed, with 64% reporting no symptoms, 17% mild, 13% moderate, and 5% severe symptoms. A total of 20 laboratory tests were ordered based on pharmacist recommendation at oral chemotherapy initiation and follow-up. The median follow-up time spent with patients was 10 minutes (IQR 10-15), and the overall median time spent on follow-up was 25 minutes (IQR 15-29).

CONCLUSION: During this pilot study, pharmacists identified drug interactions, recommended monitoring, and provided symptom assessment and recommendations for patients with leukemia who started oral chemotherapy. The results demonstrated that pharmacists have a role in oral chemotherapy monitoring and symptom management.

  1. Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs. 2003;7(6 suppl):5-9.
  2. DeCardenas R, Helfrich JS. Oral therapies and safety issues for oncology practices: patient support is key to delivering safe oral chemotherapy. Oncol Issues. 2010;25:40-42.
  3. Muluneh B, Deal A, Alexander MD, et al. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. J Oncol Pharm Pract. 2018;24:98-109.
  4. Krikorian S, Pories S, Tataronis G, et al. Adherence to oral chemotherapy: challenges and opportunities. J Oncol Pharm Pract. 2019;25:1590-1598.
  5. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652-661.
  6. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401-5411.
  7. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348-354.
  8. De Las Cuevas C, Peñate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. Int J Clin Health Psychol. 2015;15:121-129.
  9. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22:3485-3490.
  10. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557-565. Errata in: J Clin Oncol. 2016;34:2198; J Clin Oncol. 2019;37:528.
  11. Hannon B, Dyck M, Pope A, et al. Modified Edmonton Symptom Assessment System including constipation and sleep: validation in outpatients with cancer. J Pain Symptom Manage. 2015;49:945-952.
  12. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164-2171.
Related Items
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
A Pooled Safety Analysis of Loncastuximab Tesirine in Relapsed or Refractory DLBCL in the LOTIS Clinical Trial Program: Incidence, Onset, and Management of Myelosuppression
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Lymphoma
Evaluation of Empiric Double Coverage with Tobramycin for Adult Patients with Febrile Neutropenia
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Treatment Patterns, Real-World Outcomes, and Resource Use in Patients with Non–MSI-High or Mismatch Repair Proficient Advanced Endometrial Cancer
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Gynecologic Cancers
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Impact of a Remote Oncology Clinical Pharmacist Program in 4 Community Oncology Practices
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Integrated Health-System Specialty Pharmacy Support in Reducing Financial Toxicity of Oral Oncolytic Therapy
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
Perceptions of PGY2 Oncology Programs on Financial Toxicity Education and Preparedness
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts
The Impact of a Comprehensive Immunotherapy Continuing Education Curriculum on Pharmacists’ Knowledge, Competence, and Confidence
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Immunotherapy
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.